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coupled cannabinoid receptors CB1 and CB2 as well as the nuclear peroxisome proliferator-activated receptor (PPAR) family members PPARα and PPARγ (Felder et al., 1993; Munro et al., 1993; O'Sullivan, 2007) . AEA is also an endogenous agonist for the vanilloid receptor channel TRPV1 (Zygmunt et al., 1999; Smart et al., 2000) and the GRP55 receptor (Pertwee, 2002; Ryberg et al., 2007; Lauckner et al., 2008) . Cessation of AEA and 2-AG signaling occurs via a two-step process: 1) transport of endocannabinoids from the extracellular to the intracellular space, and 2) intracellular degradation by hydrolysis or oxidation.
Cellular Accumulation as a Mechanism for the Termination of Extracellular Endocannabinoid Signaling
Like typical neurotransmitters, endocannabinoids are translocated across the plasma membrane in order to cease their signaling at the extracellular cannabinoid receptors. However, the mechanism and proteins responsible for AEA and/or 2-AG transport remain elusive and hotly debated. While some researchers have proposed that these lipophilic endocannabinoids cross the cell plasma membrane via simple diffusion through the lipid bilayer (Glaser et al., 2003; Glaser et al., 2005; Kaczocha et al., 2006) , other data indicate that the uptake process is a protein-facilitated event (Hillard et al., 1997; Hillard and Jarrahian, 2000; Rakhshan et al., 2000; Beltramo and Piomelli, 2000) . Numerous studies conducted in various cell types, both of neuronal and non-neuronal origin, have characterized AEA and 2-AG uptake as being temperature-dependent, saturable, and independent of energy in the form of ion gradients or adenosine MOL #55251 triphosphate (ATP) hydrolysis (Rakhshan et al., 2000; Maccarrone et al., 2000; Hillard et al., 1997; Hillard and Jarrahian, 2003; Hermann et al., 2006; Deutsch et al., 2001; Day et al., 2001; Bisogno et al., 2001; Beltramo and Piomelli, 2000) . However, even among those in agreement with a proteinfacilitated model for endocannabinoid uptake, there remains debate concerning the precise type of protein-facilitated event responsible.
Several different models have been proposed for endocannabinoid uptake that fit under the general heading of a protein-facilitated event: 1) transmembrane carrier (Hillard and Jarrahian, 2000; Beltramo et al., 1997) ), 2) intracellular sequestration (Hillard and Jarrahian, 2003; Hillard et al., 2007) , 3) passive diffusion driven by fatty acid amide hydrolase (FAAH) (Glaser et al., 2003) , and 4) carrier-mediated caveolae-related endocytosis McFarland et al., 2008; Rakhshan et al., 2000) . The majority of these models have been suggested as a result of experiments studying AEA transport only. Evidence exists though, which suggests that 2-AG and AEA are accumulated in cells via a common mechanism(s) (Beltramo and Piomelli, 2000) .
Both 2-AG and AEA uptake have been characterized as protein-facilitated events (Bisogno et al., 2001; Beltramo and Piomelli, 2000) . Additionally, 2-AG has been shown to inhibit AEA uptake in cells, indicating a competitive nature of the two endocannabinoids with regard to transport (Bisogno et al., 2001; Beltramo and Piomelli, 2000) .
Transmembrane Carrier Protein
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6 AEA diffusion across the lipid bilayer has been proposed to be facilitated by a membrane-localized protein carrier ( Figure 1A ) Hillard et al., 1997; Hillard and Jarrahian, 2000; Ligresti et al., 2004; Beltramo et al., 1997) . Much of the evidence for the existence of a membrane-localized endocannabinoid carrier protein stems from the observation that AEA transport in cells is bidirectional (Hillard et al., 1997; Hillard and Jarrahian, 2000; Ligresti et al., 2004; Maccarrone et al., 2002) . Studies conducted in both neuronal and nonneuronal cells demonstrate AEA efflux as well as uptake (Maccarrone et al., 2002; Hillard et al., 1997) . In addition, experiments performed by Hillard and colleagues indicate that the elusive membrane-localized AEA carrier is capable of the trans-flux coupling effect, a phenomenon whereby in response to extracellular AEA, the membrane-localized carrier protein accumulates at the cell surface in the extracellular-facing direction (Hillard and Jarrahian, 2000) .
Intracellular Sequestration Model
The intracellular sequestration of endocannabinoids by a fatty acid binding protein(s) is another proposed mechanism for endocannabinoid uptake suggested by Hillard and colleagues (Hillard and Jarrahian, 2003; Hillard et al., 2007) (Figure 1B) . Interestingly, this model simultaneously supports the proposition that AEA passively diffuses across the lipid bilayer and explains the characteristics of AEA uptake consistent with a protein-facilitated process.
Following the unassisted translocation of AEA across the plasma membrane, the fatty acid-derived AEA may interact with fatty acid binding proteins (Hillard and Jarrahian, 2003) . The intracellular sequestration of AEA by these binding proteins would remove AEA from the intracellular pool of "free" AEA, thus, promoting the inward concentration gradient and AEA uptake (Hillard and Jarrahian, 2003) .
FAAH-Driven Passive Diffusion
FAAH-mediated hydrolysis of intracellular AEA does, to some extent, drive AEA uptake ( Figure 1C ). Our lab and others have shown that FAAH activity promotes AEA transport most likely by driving the concentration gradient along which AEA uptake occurs Day et al., 2001; Cravatt et al., 2001) . Cells devoid of FAAH show diminished AEA accumulation as compared to those that basally express or over-express FAAH protein Day et al., 2001) . Additionally, recent evidence suggests that most "selective" AEA uptake inhibitors also inhibit FAAH activity (DickasonChesterfield et al., 2006) . This revelation subsequently begged the question as to whether or not a specific "AEA transport protein(s)" exists.
Intracellular enzymatic degradation is probably not solely responsible for the movement of endocannabinoids across the plasma membrane. The most compelling data arguing that FAAH alone is not responsible for endocannabinoid uptake comes from work with FAAH knockout mice where cells and tissues devoid of FAAH are still capable of accumulating AEA in a saturable and pharmacologically-manipulated manner (Ortega-Gutierrez et al., 2004; Fegley et al., 2004; Ligresti et al., 2004) . Similarly, Fowler and Ghafouri showed that 2-AG uptake is not prevented by pharmacological inhibition of 2-AG hydrolysis in all cell types, indicating possible cell-specific mechanisms for 2-AG uptake, but most importantly that hydrolysis is not the sole factor mediating transport (Fowler and Ghafouri, 2008) .
Perhaps some of the most convincing evidence against FAAH being solely responsible for AEA uptake comes from the development of selective AEA uptake inhibitors. Ortar and colleagues announced their development of a series of tetrazole-based selective anandamide uptake inhibitors that do not inhibit FAAH or other metabolizing enzymes, thus, supporting the existence of a distinct protein target responsible for mediating endocannabinoid uptake (Ortar et al., 2008) . All of these data taken together suggest that, in addition to FAAH activity, a distinct protein-facilitated transport process is responsible for promoting the cellular accumulation of AEA.
Carrier-Mediated Caveolae-Related Endocytosis
Our lab has proposed that AEA uptake occurs via a protein carriermediated caveolae-related endocytic event ( Figure 1D ) (Rakhshan et al., 2000; McFarland et al., 2008) . We demonstrated that inhibition of caveolae-related endocytosis or prevention of caveolae formation both led to a significant decrease in cellular AEA accumulation, thus, implicating a role for these membrane microdomains in the AEA uptake process McFarland et al., 2008) . We propose that extracellular AEA binds a carrier protein located within caveolae, and that subsequently, caveolae-derived vesicle formation and endocytosis of the membrane-packaged endocannabinoid is induced McFarland et al., 2008; . The subsequent delivery of internalized AEA to FAAH may be a critical Catalytic degradation/modification of AEA and 2-AG not only serves as a mechanism for the augmentation of cellular uptake and cessation of extracellular signaling as mentioned above, but also regulates the intracellular signaling events of these two endocannabinoids. Below, we will briefly review the roles of the aforementioned enzymes in AEA and 2-AG metabolism.
Endocannabinoid Hydrolysis: FAAH1, FAAH2, and MAGL
FAAH1 and FAAH2 FAAH-mediated hydrolysis of AEA yields arachidonic acid and ethanolamine (Figure 2A ) (Deutsch and Chin, 1993) . Currently, two FAAH isoforms (FAAH1 and FAAH2) have been identified (Cravatt et al., 1996; Wei et (McKinney and Cravatt, 2005; Wei et al., 2006; Giang and Cravatt, 1997; . Both isoforms are integral membrane proteins, owing to a single transmembrane domain on their respective N-termini, although their orientation in the membrane differs (Cravatt et al., 1996; Wei et al., 2006) . FAAH1 has been proposed to contain a cytoplasmic-facing C-terminus, whereas the C-terminus of FAAH2 faces the lumen (Wei et al., 2006) . The two FAAH isoforms also vary in their expression patterns (Wei et al., 2006) . FAAH1 has been cloned from several different species, including mice, rats, and humans and is preferentially expressed in the brain, testis, and small intestine (McKinney and Cravatt, 2005; Wei et al., 2006) . FAAH2 is not expressed in rodents and is the predominant isoform found in cardiac tissue (Wei et al., 2006) . Also, FAAH1
has been reported to have greater activity with regard to fatty acid ethanolamides such as AEA (Wei et al., 2006) . MAGL Although some reports suggest that FAAH may also play a role in 2-AG degradation , the major enzyme responsible for 2-AG metabolism appears to be the serine hydrolase MAGL (Dinh et al., 2002) . MAGL has no sequence similarity with any member of the amidase signature protein family, including either FAAH isoform, or any other mammalian protein (Saario and Laitinen, 2007) . However, MAGL does contain the α /β-hydrolase fold common to many lipases (Saario and Laitinen, 2007) . As a proposed serine hydrolase, MAGL is capable of hydrolyzing both medium-and long-chain fatty acids (Saario and Laitinen, 2007) . MAGL-mediated hydrolysis of 2-AG yields arachidonic acid and glycerol ( Figure 2B ) (Karlsson et al., 1997) .
Overexpression and siRNA-mediated knockdown of MAGL results in increased and decreased 2-AG inactivation, respectively (Dinh et al., 2004; Dinh et al., 2002) . MAGL protein is expressed in a variety of human, rat, and mouse tissues (Saario and Laitinen, 2007; Long et al., 2009) .
Endocannabinoid Oxidation: COX-2 and the 12-and 15-Lipoxygenases
AEA and 2-AG are not only subject to hydrolysis, but because of their structure can also be metabolized by several of the same enzymes that are responsible for arachidonic acid oxidation, including COX-2 and the 12-and 15-lipoxygenases (Di .
COX-2 COX-2 is responsible for catalyzing the oxidation of AEA and 2-AG into various prostaglandin-ethanolamides (PG-EAs or prostamides) and
prostaglandin-glycerol esthers (PG-GEs), respectively ( Figure 3A and B) (Woodward et al., 2008) . Until recently, whether or not such metabolites existed in vivo was unknown. However, Hu and colleagues have provided evidence to suggest that, indeed, at least some such in vivo reactions do occur (Shu-Jung Hu et al., 2008) . Interestingly, the endocannabinoid-derived prostaglandins have unique pharmacological profiles that appear to involve as-of-yet unidentified receptors (Shu-Jung Hu et al., 2008; Woodward et al., 2008; . Figure 4A ) (Edgemond et al., 1998; Veldhuis et al., 2003) . Likewise, 12-LOX-and 15-LOX-mediated oxidation of 2-AG results in the formation of 12-and 15-hydroperoxyeicosatetraenoic acid glycerol ester (12-HETE-GE and 15-HETE-GE), respectively ( Figure 4B ) (Kozak et al., 2002; Moody et al., 2001 ).
Unlike the endocannabinoid-derived prostaglandins, the lipoxygenase derivatives of AEA and 2-AG appear to mediate their biological activities via established receptors, including the cannabinoid receptors, PPAR-α, and TRPV1 (Di Edgemond et al., 1998; Kozak et al., 2002; Craib et al., 2001 ).
Pharmacological Manipulation of Endocannabinoid Uptake and Metabolism
The cannabinoid system is currently an active research area due to the many physiological and pathophysiological implications associated with AEA and 2-AG signaling such as appetite (Kirkham and Tucci, 2006) , pain (Hohmann and Suplita, 2006) , anxiety (Witkin et al., 2005) , fertility (Wang et al., 2006) , neurodegeneration (Battista et al., 2006) , the immune response (Ashton, 2007) , and cardiac health (Ashton and Smith, 2007) . Pharmacological manipulation of endogenous AEA and 2-AG levels is one way to selectively regulate their associated signaling events for therapeutic purposes. Thus, the proteins involved in endocannabinoid uptake and metabolism, the events responsible for termination of endocannabinoid signaling, are attractive targets for pharmacological exploitation aimed at modulating AEA and 2-AG signaling.
The Search for Selective Endocannabinoid Reuptake Inhibitors (SERIs)
This article has not been copyedited and formatted. The final version may differ from this version. Unfortunately, the combination of the elusiveness of the protein(s) responsible for AEA and/or 2-AG uptake along with the unresolved relationship that exists between endocannabinoid uptake and FAAH/MAGL activity has hindered the development of SERIs. In fact, one 2006 study showed that nearly all "selective" AEA uptake inhibitors also block FAAH activity to one extent or another (Dickason-Chesterfield et al., 2006 ).
Yet, recent developments indicate that the identities of the endocannabinoid transporter(s) may soon be determined. Moore and colleagues announced their development of the potent tetrazole-based specific AEA uptake inhibitor LY2318912 (Moore et al., 2005) . This compound appears to bind a protein target distinct from FAAH and does not cross the cell membrane, supporting the hypothesis of a plasma membrane localized or associated AEA carrier (Moore et al., 2005) . Additionally, several new molecules designed to isolate and identify the putative transporter protein(s) have recently been developed, including several photo-affinity radioligands as well as a biotin-tagged AEA (Balas et al., 2005; Balas et al., 2006; Fezza et al., 2008; Moore et al., 2005; Moriello et al., 2006) . may be affected by the specificity of the inhibitor used (Trezza and Vanderschuren, 2009) . They found that the non-specific uptake inhibitor AM404 and the more-specific uptake inhibitor VDM11 had contradicting effects on the social play of rats possibly due to off-target effects elicited by AM404 that are unassociated with CB1, CB2, or TRPV1 receptors (Trezza and Vanderschuren, 2009 ). Thus, compounds that specifically inhibit endocannabinoid uptake will better elucidate the true behavioral and physiological consequences of augmented endocannabinoid signaling.
Although many compounds initially thought to be specific for the endocannabinoid transporter have been shown to also inhibit FAAH and/or MAGL, these non-specific AEA uptake inhibitors do have utility in endocannabinoid research. For instance, in vivo studies using AM404 have implicated the endocannabinoid system in the neuropathic and inflammatory pain pathways (La Rana et al., 2008; Mitchell et al., 2007) as well as in the mediation of antidepressant-like effects (Adamczyk et al., 2008) . AM404 has also been shown to reduce ethanol administration in rats, suggesting utility for the compound in the treatment of alcoholism, although the exact signaling pathway responsible for this effect is unknown (Cippitelli et al., 2007) .
Inhibitors of AEA and 2-AG Hydrolysis
In instances where increased AEA or 2-AG signaling may have therapeutic benefit such as chronic pain or anxiety, inhibition of AEA and 2-AG enzyme-mediated hydrolysis may be desirable. Specifically inhibiting FAAH could increase AEA signaling in two ways: 1) by preventing AEA hydrolysis and, 2) by decreasing the rate of AEA uptake into cells by interfering with the inward concentration gradient perpetuated by intracellular AEA hydrolysis.
In addition, the metabolites of AEA and 2-AG hydrolysis may themselves play roles in disease. For instance, 2-AG metabolites have been implicated as stimulatory factors in the pathogenesis of prostate cancer (Endsley et al., 2007) .
Endsley and colleagues observed that in the androgen-independent prostate carcinoma (PC-3) cells, exogenous application of 2-AG increased production of arachidonic acid, which is then oxidized by 12-lipoxygenase. The resulting oxidized product, 12-HETE-GE, stimulates prostate cell invasion (Endsley et al., 2007) . The authors propose that inhibition of 2-AG hydrolysis in such instances may prove to have therapeutic potential (Endsley et al., 2007) .
Over the years, a significant number of FAAH inhibitors have been developed (for a review, see Seierstad and Breitenbucher, 2008) . In addition to the development of FAAH inhibitors, some compounds currently on the market, including several NSAIDS, have been shown to inhibit FAAH activity (Fowler et al., 2001; Seierstad and Breitenbucher, 2008) . However, the development of MAGL inhibitors has lagged historically. Evidence suggests that boronic acids potently inhibit FAAH and may serve as good starting compounds for the development of better MAGL inhibitors (Minkkila et al., 2008) . Recently, Long and colleagues announced their development of a selective MAGL inhibitor JZL184 that produces antinociceptive effects, hypomotility, and hypothermia in mice (Long et al., 2009 ). This advancement offers many possibilities not only for therapeutic development of MAGL inhibitors, but also with regard to research 
Endocannabinoid-derived Oxidative Metabolites as Pharmacological Targets
There have been many pathophysiological implications for the endocannabinoid-derived oxidative metabolites produced by COX-2 and the 12-and 15-LOXs. For example, data exist suggesting that COX-2-mediated oxidation of endocannabinoids plays an important regulatory role in hippocampal neuronal transmission and synaptic plasticity (Yang et al., 2008; Sang et al., 2006) . Additionally, as briefly mentioned earlier, 12-LOX-generated oxidative metabolites of AEA may be agonists for TRPV1, a key channel in pain modulation (Craib et al., 2001) 
